September 8, 2026
BrainChild Bio
BrainChild Bio raised $116 million in Series A funding to advance its CAR T cell therapies for central nervous system tumors.
- Round
- Series A
- Amount raised
- $116M
- Lead investor
- —
- Industry
- Biotechnology
- Headquarters
- Seattle, WA
- Employees
- 11-50 employees
- Website
- brainchildbio.com
- View profile →